Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PROTAGONIST THERAPEUTICS, INC : Other Events, Financial Statements and Exhibits (form 8-K)

12/11/2020 | 06:32am EST
Item 8.01. Other Events.



Underwriting Agreement


On December 10, 2020, Protagonist Therapeutics, Inc. ("Protagonist" or "the Company") entered into an underwriting agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC, SVB Leerink LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (collectively, the "Underwriters"), relating to the public offering, issuance and sale of 4,761,904 shares of the Company's common stock, par value $0.00001 per share ( the "Common Stock"). The price to the public in this offering is $21.00 per share, and the Underwriters have agreed to purchase the shares from the Company pursuant to the Underwriting Agreement at a price of $19.74 per share. Under the terms of the Underwriting Agreement, Protagonist also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 714,285 shares of Common Stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to the Company from this offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company, or $115.0 million if the Underwriters exercise in full their option to purchase additional shares of Common Stock. The offering is expected to close on December 15, 2020, subject to customary closing conditions.

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of the Underwriting Agreement.

The offering is being made pursuant to the Company's effective registration statement on Form S-3ASR and an accompanying prospectus (Registration Statement No. 333-251254) previously filed with the SEC and a preliminary and final prospectus supplement thereunder.

The Underwriting Agreement is filed as Exhibit 1.1 to this report, and the description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of the shares in the offering is attached as Exhibit 5.1 hereto.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits.



Exhibit                                    Description

  1.1        Underwriting Agreement, dated December 10, 2020.

  5.1        Opinion of Cooley LLP.

  23.1       Consent of Cooley LLP (contained in Exhibit 5.1).

  104      Cover Page Interactive Data File (embedded within the Inline XBRL document).

© Edgar Online, source Glimpses

All news about PROTAGONIST THERAPEUTICS, INC.
01/04/C O R R E C T I O N -- Protagonist Therapeutics, Inc./
PR
2021INSIDER SELL : Protagonist Therapeutics
MT
2021Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data
CI
2021Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summi..
PR
2021Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications
MT
2021Protagonist Therapeutics Announces the Selection of Oral Peptide PN-235 into Phase 2 Cl..
PR
2021Protagonist Therapeutics Announces Selection of Oral Peptide PN-235 into Phase 2 Clinic..
CI
2021Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use ..
AQ
2021Protagonist Therapeutics Announces 'Positive Data' for Rusfertide as Possible Hereditar..
MT
2021JMP Securities Adjusts Price Target on Protagonist Therapeutics to $70 From $60, Keeps ..
MT
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 23,8 M - -
Net income 2021 -127 M - -
Net cash 2021 248 M - -
P/E ratio 2021 -11,7x
Yield 2021 -
Capitalization 1 518 M 1 518 M -
EV / Sales 2021 53,3x
EV / Sales 2022 52,9x
Nbr of Employees 116
Free-Float 98,9%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 31,81 $
Average target price 59,00 $
Spread / Average Target 85,5%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Donald A. Kalkofen Chief Financial Officer
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.0.20%1 636
MODERNA, INC.-31.46%70 577
LONZA GROUP AG-14.10%53 088
IQVIA HOLDINGS INC.-14.84%45 903
SEAGEN INC.-14.26%24 238
ICON PUBLIC LIMITED COMPANY-17.00%20 923